Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1716 ARTÍCULOS , VIENDO DEL 421 AL 435

Sleep, neuronal hyperexcitability, inflammation and neurodegeneration: Does early chronic short sleep trigger and is it the key to overcoming Alzheimer's disease?

Ahnaou A, Drinkenburg WHIM.

Neurosci Biobehav Rev. 2021 Oct;129:157-179. doi: 10.1016/j.neubiorev.2021.06.039. Epub 2021 Jun 29.

Social Network Analysis of Alzheimer's Teams: A Clinical Review and Applications in Psychiatry to Explore Interprofessional Care

Lazzari C, Kotera Y, Green P, Rabottini M.

Curr Alzheimer Res. 2021;18(5):380-398. doi: 10.2174/1567205018666210701161449.

Mitochondrial Disorders in Alzheimer's Disease

Sukhorukov VS, Mudzhiri NM, Voronkova AS, Baranich TI, Glinkina VV, Illarioshkin SN.

Biochemistry (Mosc). 2021 Jun;86(6):667-679. doi: 10.1134/S0006297921060055.

Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease

Eriksdotter M, Mitra S.

Handb Clin Neurol. 2021;179:219-229. doi: 10.1016/B978-0-12-819975-6.00012-1.

Diurnal and seasonal molecular rhythms in the human brain and their relation to Alzheimer disease

Lim ASP.

Handb Clin Neurol. 2021;179:271-284. doi: 10.1016/B978-0-12-819975-6.00017-0.

The intermediate nucleus in humans: Cytoarchitecture, chemoarchitecture, and relation to sleep, sex, and Alzheimer disease

Saper CB.

Handb Clin Neurol. 2021;179:461-469. doi: 10.1016/B978-0-12-819975-6.00030-3.

Aducanumab for Alzheimer's disease?

Walsh S, Merrick R, Milne R, Brayne C.

BMJ. 2021 Jul 5;374:n1682. doi: 10.1136/bmj.n1682.

Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?

Hershey LA, Tarawneh R.

Neurology. 2021 Sep 14;97(11):517-518. doi: 10.1212/WNL.0000000000012453. Epub 2021 Jul 7.

Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels

Cunha S, Forbes B, Sousa Lobo JM, Silva AC.

Int J Nanomedicine. 2021 Jun 29;16:4373-4390. doi: 10.2147/IJN.S305851. eCollection 2021.

A contentious FDA ruling for Alzheimer's disease

The Lancet Neurology.

Lancet Neurol. 2021 Aug;20(8):585. doi: 10.1016/S1474-4422(21)00215-5. Epub 2021 Jul 5.

Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease

Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H.

Int J Biol Sci. 2021 May 27;17(9):2181-2192. doi: 10.7150/ijbs.57078. eCollection 2021.

Therapeutic potential of ferulic acid and its derivatives in Alzheimer's disease-A systematic review

Phadke AV, Tayade AA, Khambete MP.

Chem Biol Drug Des. 2021 Nov;98(5):713-721. doi: 10.1111/cbdd.13922. Epub 2021 Jul 16.

Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial

Gulley E, Verghese J, Blumen HM, Ayers E, Wang C, Portenoy RK, Zwerling JL, Weiss E, Knotkova H.

Neurodegener Dis Manag. 2021 Aug;11(4):277-288. doi: 10.2217/nmt-2020-0061. Epub 2021 Jul 9.

The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer's disease

Pan G, King A, Wu F, Simpson-Yap S, Woodhouse A, Phipps A, Vickers JC.

Ageing Res Rev. 2021 Sep;70:101402. doi: 10.1016/j.arr.2021.101402. Epub 2021 Jul 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias